Bal Pharma Limited (BALPHARMA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bal Pharma Limited (BALPHARMA) has a cash flow conversion efficiency ratio of 0.129x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs101.16 Million ≈ $1.09 Million USD) by net assets (Rs783.30 Million ≈ $8.47 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bal Pharma Limited - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Bal Pharma Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Bal Pharma Limited for a breakdown of total debt and financial obligations.
Bal Pharma Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bal Pharma Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Winamp Group SA
PA:ALPET
|
N/A |
|
WooGene B&G Co. Ltd
KQ:018620
|
0.015x |
|
High Coast Distillery AB
ST:HIGHCO-B
|
0.005x |
|
Euro Manganese Inc
AU:EMN
|
3.412x |
|
IntegraFin Holdings plc
LSE:IHP
|
0.599x |
|
Integritas Viager SA
PA:MLVIE
|
N/A |
|
Barunson Co. Ltd
KQ:018700
|
-0.038x |
|
Caring Brands, Inc. Common Stock
NASDAQ:CABR
|
-0.507x |
Annual Cash Flow Conversion Efficiency for Bal Pharma Limited (2006–2025)
The table below shows the annual cash flow conversion efficiency of Bal Pharma Limited from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see BALPHARMA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs774.04 Million ≈ $8.37 Million |
Rs42.32 Million ≈ $457.70K |
0.055x | -83.39% |
| 2024-03-31 | Rs692.61 Million ≈ $7.49 Million |
Rs228.06 Million ≈ $2.47 Million |
0.329x | +1237.80% |
| 2023-03-31 | Rs637.02 Million ≈ $6.89 Million |
Rs-18.43 Million ≈ $-199.37K |
-0.029x | -106.11% |
| 2022-03-31 | Rs584.92 Million ≈ $6.33 Million |
Rs277.08 Million ≈ $3.00 Million |
0.474x | +16.04% |
| 2021-03-31 | Rs533.54 Million ≈ $5.77 Million |
Rs217.81 Million ≈ $2.36 Million |
0.408x | -19.88% |
| 2020-03-31 | Rs453.38 Million ≈ $4.90 Million |
Rs231.01 Million ≈ $2.50 Million |
0.510x | +295.55% |
| 2019-03-31 | Rs602.21 Million ≈ $6.51 Million |
Rs77.58 Million ≈ $838.95K |
0.129x | +1663.52% |
| 2018-03-31 | Rs602.01 Million ≈ $6.51 Million |
Rs-4.96 Million ≈ $-53.64K |
-0.008x | -108.44% |
| 2017-03-31 | Rs600.31 Million ≈ $6.49 Million |
Rs58.58 Million ≈ $633.56K |
0.098x | +127.59% |
| 2016-03-31 | Rs547.22 Million ≈ $5.92 Million |
Rs-193.53 Million ≈ $-2.09 Million |
-0.354x | -234.25% |
| 2015-03-31 | Rs551.68 Million ≈ $5.97 Million |
Rs145.33 Million ≈ $1.57 Million |
0.263x | -0.97% |
| 2014-03-31 | Rs500.50 Million ≈ $5.41 Million |
Rs133.13 Million ≈ $1.44 Million |
0.266x | -27.36% |
| 2013-03-31 | Rs446.18 Million ≈ $4.83 Million |
Rs163.39 Million ≈ $1.77 Million |
0.366x | +14.07% |
| 2012-03-31 | Rs400.56 Million ≈ $4.33 Million |
Rs128.58 Million ≈ $1.39 Million |
0.321x | +151.97% |
| 2011-03-31 | Rs361.75 Million ≈ $3.91 Million |
Rs46.09 Million ≈ $498.42K |
0.127x | +187.92% |
| 2010-03-31 | Rs357.62 Million ≈ $3.87 Million |
Rs-51.82 Million ≈ $-560.40K |
-0.145x | -142.27% |
| 2009-03-31 | Rs372.35 Million ≈ $4.03 Million |
Rs127.64 Million ≈ $1.38 Million |
0.343x | +32.33% |
| 2008-03-31 | Rs350.32 Million ≈ $3.79 Million |
Rs90.75 Million ≈ $981.39K |
0.259x | +67.86% |
| 2007-03-31 | Rs334.02 Million ≈ $3.61 Million |
Rs51.55 Million ≈ $557.46K |
0.154x | +183.48% |
| 2006-03-31 | Rs323.02 Million ≈ $3.49 Million |
Rs-59.71 Million ≈ $-645.75K |
-0.185x | -- |
About Bal Pharma Limited
Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Az… Read more